Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2022-06-21 00:00:00 ET · period of report 2022-06-16 · accession 0001209191-22-038480 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-21 | 2022-06-16 | DFTX | Barrow Robert | CEO, Dir | S - Sale | $0.7 | -21.3K | 3.96M | -0.5% | -$14.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-06-16 | S | D | 21,275 | $0.7 | 3,955,619 | D | — | — | (F2) The Common Shares were sold in one transaction at a price of $0.91 CAD Dollars. This represents the price in United States Dollars using the conversion rate on June 16, 2022. |